Gsk (GSK) Retained Earnings (2009 - 2026)
Gsk (GSK) posted quarterly Retained Earnings of $1.8 billion for Q2 2026, up 14.98% year-over-year from $1.5 billion in Q2 2025, and down 6.28% quarter-over-quarter from $1.9 billion in Q1 2026.
Gsk (GSK) Retained Earnings (2009 - 2026) Analysis & Trends
Gsk's Retained Earnings history runs 18 years deep, the most recent figure standing at $1.8 billion for Q2 2026.
- In Q2 2026, Retained Earnings rose 14.98% year-over-year to $1.8 billion; the TTM figure through Jun 2026 stood at $1.8 billion (up 14.98% YoY), while the FY2025 annual figure was $1.7 billion, down 82.52% from the prior year.
- Retained Earnings for Q2 2026 stood at $1.8 billion, down from $1.9 billion in the prior quarter.
- The five-year high for Retained Earnings was $10.0 billion in Q4 2024, with the low at -$361.3 million in Q4 2022.
- The 5-year median for Retained Earnings is $1.7 billion (2025), against an average of $2.0 billion.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings plunged 110.88% in 2022, then soared 36745.51% in 2024.
- Gsk's Retained Earnings stood at -$361.3 million in 2022, then jumped by 92.44% to -$27.3 million in 2023, then surged by 36745.51% to $10.0 billion in 2024, then slumped by 82.44% to $1.8 billion in 2025, then increased by 1.17% to $1.8 billion in 2026.
- Business Quant data shows GSK's Retained Earnings at $1.8 billion in Q2 2026, $1.9 billion in Q1 2026, and $1.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.78 Bn |
| Mar 31, 2026 | 1.90 Bn |
| Dec 31, 2025 | 1.76 Bn |
| Sep 30, 2025 | 1.75 Bn |
| Jun 30, 2025 | 1.55 Bn |
| Mar 31, 2025 | 1.28 Bn |
| Dec 31, 2024 | 10.01 Bn |
| Sep 30, 2024 | 1.30 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Mar 31, 2024 | 1.38 Bn |
| Dec 31, 2023 | -27.31 Mn |
| Sep 30, 2023 | 1.67 Bn |
| Jun 30, 2023 | 1.85 Bn |
| Mar 31, 2023 | 1.66 Bn |
| Dec 31, 2022 | -361.26 Mn |
| Sep 30, 2022 | 2.09 Bn |
| Jun 30, 2022 | 2.22 Bn |
| Mar 31, 2022 | 2.36 Bn |
| Dec 31, 2021 | 3.32 Bn |
| Sep 30, 2021 | 4.13 Bn |